1. [Effects of rosiglitazone on inflammatory reaction and insulin resistance in obese patients with newly diagnosed type 2 diabetes].
- Author
-
Zhu HL, Yu RM, Huang XZ, and Huang W
- Subjects
- Adult, Aged, Aged, 80 and over, C-Reactive Protein metabolism, Diabetes Mellitus, Type 2 blood, Diabetes Mellitus, Type 2 complications, Female, Humans, Hypoglycemic Agents therapeutic use, Inflammation blood, Interleukin-1beta blood, Interleukin-6 blood, Male, Middle Aged, Rosiglitazone, Tumor Necrosis Factor-alpha blood, Diabetes Mellitus, Type 2 drug therapy, Inflammation prevention & control, Insulin Resistance, Obesity complications, Thiazolidinediones therapeutic use
- Abstract
Objective: To study the effect of rosiglitazone on serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and insulin resistance in obese patients with newly diagnosed type 2 diabetes., Methods: This study involved 118 patients with newly diagnosed type 2 diabetes and obesity, who were randomly assigned into two groups for a 12-week treatment with rosiglitazone (4 mg/day, group A) or sulfonylureas (group B). Serum hs-CRP, IL-1beta, IL-6, TNF-alpha, fasting plasma glucose (FPG) and fasting insulin (FINS) were measured before and after the treatment. Insulin resistance index was calculated according to the HOMA Model., Results: In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). No difference in FPG was found between the two groups after the treatment (P>0.05), but serum hs-CRP, IL-1beta, IL-6, TNF-alpha and insulin resistance index were significantly lower in group A than in group B (P<0.05)., Conclusion: Rosiglitazone can decrease FPG, reduce the inflammation reaction and improve insulin resistance in obese patients with type 2 diabetes.
- Published
- 2008